|
KMID : 0358420100530111007
|
|
Korean Journal of Obstetrics and Gynecology
2010 Volume.53 No. 11 p.1007 ~ p.1013
|
|
|
Outcomes after bleomycin, etoposide and cisplatin combination chemotherapy in patients with ovarian yolk sac tumor
|
|
Kim Ji-Young
Shin You-Jung
Moon Jei-Won
Park Jeong-Yeol
Kim Dae-Yeon
Lee Joo-Hak
Kim Jong-Hyeok
Kim Yong-Man
Kim Young-Tak
Nam Joo-Hyun
|
|
|
Abstract
|
|
|
Purpose: The aim of this study was to evaluate the oncologic and reproductive outcomes of patients with ovarian yolk sac tumor after bleomycin, etoposide, cisplatin (BEP) chemotherapy following surgery.
Methods: Of 145 patients with histologically confirmed malignant ovarian germ cell tumor, 43 had yolk sac tumor and received BEP chemotherapy after surgery. A retrospective analysis of these patients was performed.
Results:The mean age of 43 patients was 24.8 years (range, 7 to 59 years). Thirty eight patients were nulliparous. Of 179 BEP chemotherapy cycles, grade 1~2 hematologic and non-hematologic adverse events occurred in 46 cycles in 21 patients. Thirty nine patients showed complete remission, 1 patient showed partial remission, and 3 patient had progressive disease during BEP chemotherapy. After median follow-up time of 57 months (range, 3 to 153 months), 5 patients had recurrent disease and three of them died of disease. The 5-year recurrence free survival rate and overall survival rate were 86% and 94%, respectively. After chemotherapy, all but one premenarchal patients had normal menstruation. Of them 5 patients tried to conceive and 3 of them succeeded in pregnancy.
Conclusions:BEP chemotherapy was very safe and effective in patients with ovarian yolk sac tumor. Survival outcomes are excellent and reproductive outcomes are promising after BEP chemotherapy.
|
|
|
KEYWORD
|
|
|
Malignant ovarian germ cell tumor, Yolk sac tumor, Bleomycin, Etoposide, Cisplatin
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|